Last Price | 18.82 | Max Price | 19.10 |
Min Price | 16.67 | 1 Year return | 41.82 |
Avg. Target | 21.12 | Expected Return | 12.25 % |
Sector | Health Care | Subsector | Health Care Eq. & Services |
Sell | 0 | Rating | |
Hold | 1 | Concensus | |
Buy | 3 | ||
Annual report 2017 |
Fagron (the former Arseus) is a European Group of corporation that was founded in the year 1998 by the execution of a buy-and-build strategy which was augmented by its strong organic growth. Fagron is an international group of business entities that offers products, services and several notions for professionals and institutions which are active in the healthcare division across Europe, North America, South America, Asia and Australia. Fagron is subdivided into four divisions and is on the go in the markets for magisterial arrangements for pharmacies, dental stuff, medical and surgical goods and medical IT solutions. The Fagron NV is a Belgian company that is situated in Waregem, and the company is listed on Euronext Brussels and Euronext Amsterdam. The operational performances of the Fagron group are determined by the Dutch company Fagron BV. The headquarters of Fagron BV is based in Rotterdam. Fagron service-oriented establishment provides an innovative and customized products and solutions as per their customer needs. Fagron aspires to confine a primary position in each & every market or in the product segment in which it functions.
Fagron with popular home brands, elite distribution agreements and high added value, the company is competent enough to distinguish itself from its rival. Fagron as a Group are considered best to use their knowledge, consumer insight and economies of scale to provide simple, sound and well-organized ways of working. The company provides employment to more than 2,500 employees who work in collaboration and dynamically exchange information and expertise with each other. This permits Fagron to take action quickly, increase productivity and precisely to fulfil customer wishes together with lead to develop their position in the markets. Fagron is looking for a sustainable expansion along with retaining its primary position in certain segments of the specialized healthcare sector and also to develop through organic augmentation and a dynamic buy-and-build approach.
On 5 October 2007 Fagron NV got listed in the NYSE Euronext Brussels and Euronext Amsterdam also its share are incorporated in another index like BEL MID and Amsterdam Small Cap Index (AScX). Fagron offers products, services and entire solutions to the healthcare sector in Europe, North America, South America, Asia and Australia. The activities are subdivided into four divisions. First one is Fagron, which is a global market leader in products and concepts for pharmaceutical compounding. Other is Corilus, which supplies ICT entire solutions for medical specialists in Belgium, Netherlands and France. Another is Healthcare Solutions, which entirely focuses on the dental and medical giving out activities of Fagron. Last but not the least Healthcare Specialties, which concentrates on developing and introducing of pioneering dental and medical solutions and products. Fagron endeavour to get the number 1 position in every market and in each segment in which the company is active. With over 2,500 employees in more than 30 countries globally. In the year 2012 Fagron reported a turnover of 547 Million Euros.
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 535 | 2,019,579 | 0.03 % |
2020 | 556 | 2,170,517 | 0.03 % |
2021 | 574 | 2,404,876 | 0.02 % |
2022 | 684 | 2,645,792 | 0.03 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
Fagron mainly operates in the health care eq. & services sector. The global health care companies gained over the past 10 years on average 102 percent. Since 2011 the sector is 64 percent higher and over the past year plus 102 percent.
Over the period from December 2015 till December 2016 the stock gained around 47 percent. Fagron' stock lost the past 5 years at around 13 percent. Fagron's revenues between 2011 and 2015 were relatively stable and moved between 547,02 million euros and 473 million euros. Fagron's net results between 2011 and 2015 were quite unstable and moved between 28,14 million euros and -202,28 million euros.
Fagron paid out dividends in the past 5 years. On average the Fagron stock yielded a delivered a dividend yield of around 2,24 percent over the past 5 years.
At the end of 2015 around 1950 thousand people were employed at Fagron.
At the end of 2015 the health care company's balance sheet equaled 689,38 million euros. At the end of 2015 the total debt positon equaled 756,85 million euros. This is around 109,79 percent of the total balance sheet. At the end of 2016 the Belgian company was traded with a price/earnings-ratio of around -19. So investors paid -19 times the company's 2015's EPS. Based on the classical stock valuation theories the Belgian stock can be seen as a value stock.
The health care company's market capitalization (the number of shares outstanding times the market value) equaled around 234,78 million euros. At the end of 2015 the Belgian company had around 31,3 million stocks listed.
On this page you can find all Fagron's financial reports. More information about Fagron can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
473
|
422
|
437
|
472
|
535
|
556
|
Costs |
675
|
442
|
390
|
429
|
494
|
496
|
Profit |
-202
|
-21
|
47
|
42
|
41
|
60
|
Margin of profit |
-42.78
|
-4.87
|
10.68
|
9.01
|
7.68
|
10.72
|
ROI |
299.88
|
-13.73
|
25.72
|
20.64
|
16.96
|
23.55
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
-67
|
150
|
181
|
206
|
242
|
253
|
Debt |
757
|
718
|
413
|
477
|
559
|
500
|
Total assets |
689
|
868
|
594
|
683
|
801
|
753
|
Solvency |
-9.79
|
17.26
|
30.54
|
30.15
|
30.21
|
33.62
|
Cash |
75
|
75
|
61
|
78
|
107
|
84
|
Cashflow |
73
|
68
|
84
|
73
|
77
|
93
|
Employees |
2,017
|
1,991
|
2,054
|
0
|
0
|
|
Revenue per employee |
0.23
|
0.21
|
0.21
|
0.0
|
0.0
|
|
Cashflow / Debt |
0.10
|
0.09
|
0.20
|
0.15
|
0.14
|
0.19
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
6.56
|
9.71
|
11.42
|
14.28
|
19.33
|
Eps |
-0.38
|
0.65
|
0.59
|
0.56
|
0.82
|
Price/earnings-ratio |
-17.26
|
14.94
|
19.36
|
25.50
|
22.95
|
Dividend |
0.0
|
0.07
|
0.08
|
0.06
|
0.13
|
Dividend % |
0.00 %
|
0.72 %
|
0.70 %
|
0.42 %
|
0.69 %
|
Payout % |
0.0
|
0.11
|
0.14
|
0.11
|
0.16
|
Book value |
2.09
|
2.53
|
2.87
|
3.36
|
3.50
|
Market to book |
0.32
|
0.26
|
0.25
|
0.24
|
0.19
|
Cashflow per stock |
0.94
|
1.17
|
1.02
|
1.07
|
1.28
|
Stocks |
72
|
72
|
72
|
72
|
72
|
Market Cap |
470.62
|
696.60
|
819.27
|
1.029.24
|
1.362.08
|
Date
|
Price
|
---|---|
13 Nov 2024
|
18.82
|
08 Nov 2024
|
18.80
|
05 Nov 2024
|
18.68
|
31 Oct 2024
|
18.52
|
29 Oct 2024
|
18.90
|
23 Oct 2024
|
18.84
|
19 Oct 2024
|
18.82
|
16 Oct 2024
|
18.74
|
14 Oct 2024
|
18.70
|
05 Oct 2024
|
17.96
|
02 Oct 2024
|
18.42
|
27 Sep 2024
|
18.42
|
20 Sep 2024
|
18.78
|
17 Sep 2024
|
18.92
|
13 Sep 2024
|
19.06
|
28 Aug 2024
|
18.84
|
26 Aug 2024
|
18.96
|
23 Aug 2024
|
18.96
|
11 Aug 2024
|
19.10
|
07 Aug 2024
|
19.06
|
05 Aug 2024
|
18.94
|
01 Aug 2024
|
19.04
|
30 Jul 2024
|
18.94
|
26 Jul 2024
|
18.66
|
23 Jul 2024
|
18.76
|
16 Jul 2024
|
18.46
|
10 Jul 2024
|
18.38
|
09 Jul 2024
|
18.36
|
04 Jul 2024
|
17.92
|
02 Jul 2024
|
18.18
|